Amneal Reports First Quarter 2024 Financial Results
Amneal Pharmaceuticals, Inc. reported a Q1 2024 net revenue of $659 million, with a GAAP net loss of $92 million and diluted loss per share of $0.30. Adjusted EBITDA was $152 million with adjusted diluted EPS of $0.14. The company settled a nationwide opioids case and affirmed its 2024 full-year guidance.
Record levels of revenues in Q1 2024 with all three business segments showing double-digit growth.
Net revenue increased by 18% to $659 million compared to the first quarter of 2023.
Adjusted EBITDA rose by 31% to $152 million due to strong revenue performance and higher gross margins.
Specialty revenues increased by 15% driven by promoted products in Neurology and Endocrinology.
Company has reached a settlement in principle on a nationwide opioids settlement, payable over ten years.
Affirming 2024 full-year guidance with net revenue expected to be $2.55 billion - $2.65 billion.
Net loss attributable to Amneal Pharmaceuticals, Inc. was $92 million in Q1 2024 compared to $7 million in Q1 2023.
Company recorded a charge of $94 million in Q1 2024 for the settlement in principle on a nationwide opioids settlement.
Diluted loss per share in Q1 2024 was $0.30 compared to $0.05 for Q1 2023.
Adjusted diluted earnings per share decreased slightly to $0.14 from $0.12 in Q1 2023.
Insights
Amneal Pharmaceuticals’ Q1 2024 revenue marks an impressive 18% increase to
The company's commitment to affirming the full year 2024 guidance suggests confidence in their operational strategy and market position. However, investors should note the volatility associated with legal settlements and their potential to obscure the real operating performance. Despite the short-term financial hit, the settlement potentially eliminates uncertainty and future legal risks associated with opioid litigation, which could be seen as a positive move in the long term.
The growth in generics, which increased by
The opioid settlement, while financially burdensome in the short term, may improve Amneal's corporate image and contribute to public health through the provision of naloxone nasal spray. This kind of proactive management of legal issues is often looked upon favorably by stakeholders and could mitigate long-term reputational risk.
The opioids settlement is a critical aspect of this report. The
‒ Q1 2024 Net Revenue of
‒ Adjusted EBITDA of
‒ Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years ‒
‒ Affirming 2024 Full Year Guidance ‒
“We are extremely pleased with our outstanding start to the year, as Amneal generated record levels of revenues in the first quarter. For the first time, all three segments across our diversified business produced double-digit top-line growth in the same quarter. With perpetual and rising demand for medicines and exacerbated by chronic supply shortages in the
First Quarter 2024 Results
Net revenue in the first quarter of 2024 was
Net loss attributable to Amneal Pharmaceuticals, Inc. was
Adjusted EBITDA in the first quarter of 2024 was
Diluted loss per share in the first quarter of 2024 was
The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section for more information. In the tables below, GAAP to non-GAAP reconciliations are presented.
Settlement in Principle on a Nationwide Opioids Settlement
Amneal has reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American Tribal Nations across
In the first quarter of 2024, the Company recorded a charge of
Affirming Full Year 2024 Guidance
The Company is affirming its previously provided full year 2024 guidance.
Net revenue |
|
Adjusted EBITDA (1) |
|
Adjusted diluted EPS (2) |
|
Operating cash flow (3) |
|
Capital expenditures |
|
(1) |
Includes |
|
(2) |
Accounts for |
|
(3) |
Does not contemplate one-time and non-recurring items such as legal settlements and other discrete items. |
Amneal’s 2024 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in
Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, May 3, 2024, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.
Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the impact of a prolonged business interruption within our supply chain; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted EPS, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income, which is net loss adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for income taxes, (iii) amortization, (iv) stock-based compensation, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) charges related to certain legal matters, including interest, net, (viii) asset impairment charges, (ix) change in fair value of contingent consideration, (x) increase in tax receivable agreement liability, (xi) system implementation expense, (xii) other and (xiii) net income attributable to non-controlling interests not associated with Class B common stock, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three months ended March 31, 2024 was calculated using the weighted average fully diluted shares outstanding of Class A common stock. Non-GAAP adjusted diluted EPS for the three months ended March 31, 2023 was calculated using the weighted average diluted shares outstanding of Class A common stock and assuming all shares of Class B common stock were converted to shares of Class A common stock as of January 1, 2023.
Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations and trends while viewing the information through the eyes of management.
These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.
A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited; $ in thousands, except per share amounts)
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Net revenue |
$ |
659,191 |
|
|
$ |
557,540 |
|
Cost of goods sold |
|
421,131 |
|
|
|
379,354 |
|
Gross profit |
|
238,060 |
|
|
|
178,186 |
|
Selling, general and administrative |
|
112,595 |
|
|
|
102,096 |
|
Research and development |
|
39,298 |
|
|
|
38,690 |
|
Intellectual property legal development expenses |
|
984 |
|
|
|
1,644 |
|
Restructuring and other charges |
|
1,470 |
|
|
|
510 |
|
Change in fair value of contingent consideration |
|
100 |
|
|
|
2,457 |
|
Charges (credit) related to legal matters, net |
|
94,359 |
|
|
|
(436 |
) |
Other operating income |
|
— |
|
|
|
(1,224 |
) |
Operating (loss) income |
|
(10,746 |
) |
|
|
34,449 |
|
Other (expense) income: |
|
|
|
||||
Interest expense, net |
|
(65,703 |
) |
|
|
(49,315 |
) |
Foreign exchange (loss) gain, net |
|
(1,197 |
) |
|
|
1,901 |
|
Increase in tax receivable agreement liability |
|
(1,948 |
) |
|
|
(826 |
) |
Other income, net |
|
4,072 |
|
|
|
4,365 |
|
Total other expense, net |
|
(64,776 |
) |
|
|
(43,875 |
) |
Loss before income taxes |
|
(75,522 |
) |
|
|
(9,426 |
) |
Provision for income taxes |
|
6,156 |
|
|
|
668 |
|
Net loss |
|
(81,678 |
) |
|
|
(10,094 |
) |
Less: Net (income) loss attributable to non-controlling interests |
|
(9,965 |
) |
|
|
3,151 |
|
Net loss attributable to Amneal Pharmaceuticals, Inc. |
$ |
(91,643 |
) |
|
$ |
(6,943 |
) |
|
|
|
|
||||
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: |
|
|
|
||||
Basic and diluted |
$ |
(0.30 |
) |
|
$ |
(0.05 |
) |
Weighted-average common shares outstanding: |
|
|
|
||||
Basic and diluted |
|
307,279 |
|
|
|
152,109 |
|
Amneal Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited; $ in thousands)
|
March 31, 2024 |
|
December 31, 2023 |
|||
Assets |
|
|
|
|||
Current assets: |
|
|
|
|||
Cash and cash equivalents |
$ |
46,520 |
|
|
$ |
91,542 |
Restricted cash |
|
5,097 |
|
|
|
7,565 |
Trade accounts receivable, net |
|
668,955 |
|
|
|
613,732 |
Inventories |
|
570,653 |
|
|
|
581,384 |
Prepaid expenses and other current assets |
|
87,298 |
|
|
|
82,685 |
Related party receivables |
|
1,521 |
|
|
|
955 |
Total current assets |
|
1,380,044 |
|
|
|
1,377,863 |
Property, plant and equipment, net |
|
439,815 |
|
|
|
447,574 |
Goodwill |
|
598,549 |
|
|
|
598,629 |
Intangible assets, net |
|
859,272 |
|
|
|
890,423 |
Operating lease right-of-use assets |
|
32,970 |
|
|
|
30,329 |
Operating lease right-of-use assets - related party |
|
12,468 |
|
|
|
12,954 |
Financing lease right-of-use assets |
|
59,532 |
|
|
|
59,280 |
Other assets |
|
73,747 |
|
|
|
55,517 |
Total assets |
$ |
3,456,397 |
|
|
$ |
3,472,569 |
Liabilities and Stockholders' (Deficiency) Equity |
|
|
|
|||
Current liabilities: |
|
|
|
|||
Accounts payable and accrued expenses |
$ |
558,518 |
|
|
$ |
534,662 |
Current portion of liabilities for legal matters |
|
30,130 |
|
|
|
76,988 |
Revolving credit facility |
|
179,000 |
|
|
|
179,000 |
Current portion of long-term debt, net |
|
33,660 |
|
|
|
34,125 |
Current portion of operating lease liabilities |
|
9,508 |
|
|
|
9,207 |
Current portion of operating lease liabilities - related party |
|
3,192 |
|
|
|
2,825 |
Current portion of financing lease liabilities |
|
3,305 |
|
|
|
2,467 |
Related party payables - short term |
|
17,075 |
|
|
|
7,321 |
Total current liabilities |
|
834,388 |
|
|
|
846,595 |
Long-term debt, net |
|
2,377,707 |
|
|
|
2,386,004 |
Note payable - related party |
|
41,893 |
|
|
|
41,447 |
Operating lease liabilities |
|
26,786 |
|
|
|
24,095 |
Operating lease liabilities - related party |
|
11,969 |
|
|
|
12,787 |
Financing lease liabilities |
|
58,809 |
|
|
|
58,566 |
Related party payables - long term |
|
11,394 |
|
|
|
11,776 |
Liabilities for legal matters - long term |
|
85,479 |
|
|
|
316 |
Other long-term liabilities |
|
24,579 |
|
|
|
29,679 |
Total long-term liabilities |
|
2,638,616 |
|
|
|
2,564,670 |
Redeemable non-controlling interests |
|
47,022 |
|
|
|
41,293 |
Total stockholders' (deficiency) equity |
|
(63,629 |
) |
|
|
20,011 |
Total liabilities and stockholders' (deficiency) equity |
$ |
3,456,397 |
|
|
$ |
3,472,569 |
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(unaudited; $ in thousands)
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(81,678 |
) |
|
$ |
(10,094 |
) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
55,528 |
|
|
|
58,150 |
|
Unrealized foreign currency loss (gain) |
|
1,511 |
|
|
|
(1,987 |
) |
Amortization of debt issuance costs and discount |
|
288 |
|
|
|
2,058 |
|
Intangible asset impairment charges |
|
920 |
|
|
|
— |
|
Change in fair value of contingent consideration |
|
100 |
|
|
|
2,457 |
|
Stock-based compensation |
|
6,722 |
|
|
|
7,596 |
|
Inventory provision |
|
22,923 |
|
|
|
25,204 |
|
Other operating charges and credits, net |
|
1,250 |
|
|
|
2,047 |
|
Changes in assets and liabilities: |
|
|
|
||||
Trade accounts receivable, net |
|
(55,173 |
) |
|
|
195,970 |
|
Inventories |
|
(12,200 |
) |
|
|
(22,508 |
) |
Prepaid expenses, other current assets and other assets |
|
(11,708 |
) |
|
|
29,160 |
|
Related party receivables |
|
(562 |
) |
|
|
470 |
|
Accounts payable, accrued expenses and other liabilities |
|
62,174 |
|
|
|
(150,483 |
) |
Related party payables |
|
5,495 |
|
|
|
1,672 |
|
Net cash (used in) provided by operating activities |
|
(4,410 |
) |
|
|
139,712 |
|
Cash flows from investing activities: |
|
|
|
||||
Purchases of property, plant and equipment |
|
(9,198 |
) |
|
|
(9,688 |
) |
Acquisition of intangible assets |
|
(9,700 |
) |
|
|
(338 |
) |
Deposits for future acquisition of property, plant and equipment |
|
(862 |
) |
|
|
(1,711 |
) |
Net cash used in investing activities |
|
(19,760 |
) |
|
|
(11,737 |
) |
Cash flows from financing activities: |
|
|
|
||||
Payments of principal on debt, revolving credit facilities, financing leases and other |
|
(63,377 |
) |
|
|
(72,659 |
) |
Borrowings on revolving credit facilities |
|
48,000 |
|
|
|
80,000 |
|
Proceeds from exercise of stock options |
|
28 |
|
|
|
— |
|
Employee payroll tax withholding on restricted stock unit vesting |
|
(7,212 |
) |
|
|
(2,022 |
) |
Tax distributions to non-controlling interests |
|
(594 |
) |
|
|
(18,219 |
) |
Net cash used in financing activities |
|
(23,155 |
) |
|
|
(12,900 |
) |
Effect of foreign exchange rate on cash |
|
(165 |
) |
|
|
767 |
|
Net (decrease) increase in cash, cash equivalents, and restricted cash |
|
(47,490 |
) |
|
|
115,842 |
|
Cash, cash equivalents, and restricted cash - beginning of period |
|
99,107 |
|
|
|
35,227 |
|
Cash, cash equivalents, and restricted cash - end of period |
$ |
51,617 |
|
|
$ |
151,069 |
|
Cash and cash equivalents - end of period |
$ |
46,520 |
|
|
$ |
144,674 |
|
Restricted cash - end of period |
|
5,097 |
|
|
|
6,395 |
|
Cash, cash equivalents, and restricted cash - end of period |
$ |
51,617 |
|
|
$ |
151,069 |
|
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, $ in thousands)
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Net loss |
$ |
(81,678 |
) |
|
$ |
(10,094 |
) |
Adjusted to add: |
|
|
|
||||
Interest expense, net |
|
65,703 |
|
|
|
49,315 |
|
Provision for income taxes |
|
6,156 |
|
|
|
668 |
|
Depreciation and amortization |
|
55,528 |
|
|
|
58,150 |
|
EBITDA (Non-GAAP) |
$ |
45,709 |
|
|
$ |
98,039 |
|
Adjusted to add (deduct): |
|
|
|
||||
Stock-based compensation expense |
|
6,506 |
|
|
|
7,596 |
|
Acquisition, site closure, and idle facility expenses (1) |
|
444 |
|
|
|
2,701 |
|
Restructuring and other charges |
|
1,470 |
|
|
|
411 |
|
Charges related to legal matters, net (2) |
|
94,359 |
|
|
|
4,064 |
|
Asset impairment charges |
|
1,015 |
|
|
|
733 |
|
Foreign exchange loss (gain) |
|
1,197 |
|
|
|
(1,901 |
) |
Change in fair value of contingent consideration |
|
100 |
|
|
|
2,457 |
|
Increase in tax receivable agreement liability |
|
1,948 |
|
|
|
826 |
|
System implementation expense (3) |
|
917 |
|
|
|
771 |
|
Other |
|
(1,314 |
) |
|
|
483 |
|
Adjusted EBITDA (Non-GAAP) |
$ |
152,351 |
|
|
$ |
116,180 |
|
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited; in thousands, except per share amounts)
Reconciliation of Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
|
|
2023 |
|
Net loss |
$ |
(81,678 |
) |
|
$ |
(10,094 |
) |
Adjusted to add (deduct): |
|
|
|
||||
Non-cash interest |
|
82 |
|
|
|
1,841 |
|
GAAP provision for income taxes |
|
6,156 |
|
|
|
668 |
|
Amortization |
|
38,671 |
|
|
|
39,611 |
|
Stock-based compensation expense |
|
6,506 |
|
|
|
7,596 |
|
Acquisition, site closure expenses, and idle facility expenses (1) |
|
444 |
|
|
|
2,701 |
|
Restructuring and other charges |
|
1,453 |
|
|
|
411 |
|
Charges related to legal matters, including interest, net (2) |
|
94,486 |
|
|
|
4,882 |
|
Asset impairment charges |
|
1,015 |
|
|
|
733 |
|
Change in fair value of contingent consideration |
|
100 |
|
|
|
2,457 |
|
Increase in tax receivable agreement liability |
|
1,948 |
|
|
|
826 |
|
System implementation expense (3) |
|
917 |
|
|
|
771 |
|
Other |
|
(1,314 |
) |
|
|
632 |
|
Provision for income taxes (4) |
|
(14,341 |
) |
|
|
(10,829 |
) |
Net income attributable to non-controlling interests not associated with our Class B common stock |
|
(9,965 |
) |
|
|
(5,395 |
) |
Adjusted net income (Non-GAAP) |
$ |
44,480 |
|
|
$ |
36,811 |
|
Weighted average diluted shares outstanding (Non-GAAP) (5) |
|
316,559 |
|
|
|
306,370 |
|
Adjusted diluted earnings per share (Non-GAAP) |
$ |
0.14 |
|
|
$ |
0.12 |
|
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited)
Explanations for Reconciliations of Net Loss to EBITDA and Adjusted EBITDA and Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share
(1) |
Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2024 primarily included rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our |
|
(2) |
For the three months ended March 31, 2024, charges related to legal matters, net were associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American Tribal Nations across |
|
(3) |
System implementation expense for the three months ended March 31, 2024 and 2023 was primarily for the implementation of (i) indirect procurement software; (ii) sales deduction software; and (iii) financial statement consolidation software to further integrate our acquired businesses. |
|
(4) |
The non-GAAP effective tax rates for the three months ended March 31, 2024 and 2023 were |
|
(5) |
Weighted average diluted shares outstanding for the three months ended March 31, 2024 consisted of fully diluted Class A common stock. Weighted average diluted shares outstanding for the three months ended March 31, 2023 consisted of diluted Class A common stock and Class B common stock, as if all shares of Class B common stock were converted to Class A common stock as of January 1, 2023. |
Amneal Pharmaceuticals, Inc.
Generics Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(unaudited; $ in thousands)
|
Three Months Ended March 31, 2024 |
|
Three Months Ended March 31, 2023 |
||||||||||||||||||||
|
As Reported |
|
Adjustments |
|
Non-GAAP |
|
As Reported |
|
Adjustments |
|
Non-GAAP |
||||||||||||
Net revenue |
$ |
391,294 |
|
|
$ |
— |
|
|
$ |
391,294 |
|
|
$ |
343,806 |
|
|
$ |
— |
|
|
$ |
343,806 |
|
Cost of goods sold (2) |
|
239,922 |
|
|
|
(12,268 |
) |
|
|
227,654 |
|
|
|
230,551 |
|
|
|
(15,442 |
) |
|
|
215,109 |
|
Gross profit |
|
151,372 |
|
|
|
12,268 |
|
|
|
163,640 |
|
|
|
113,255 |
|
|
|
15,442 |
|
|
|
128,697 |
|
Gross margin % |
|
38.7 |
% |
|
|
|
|
41.8 |
% |
|
|
32.9 |
% |
|
|
|
|
37.4 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Selling, general and administrative (3) |
|
33,085 |
|
|
|
(1,729 |
) |
|
|
31,356 |
|
|
|
27,600 |
|
|
|
(1,279 |
) |
|
|
26,321 |
|
Research and development (4) |
|
34,371 |
|
|
|
(655 |
) |
|
|
33,716 |
|
|
|
32,359 |
|
|
|
(943 |
) |
|
|
31,416 |
|
Intellectual property legal development expenses |
|
960 |
|
|
|
— |
|
|
|
960 |
|
|
|
1,624 |
|
|
|
— |
|
|
|
1,624 |
|
Restructuring and other charges |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
99 |
|
|
|
— |
|
|
|
99 |
|
Charges (credit) related to legal matters, net (5) |
|
94,359 |
|
|
|
(94,359 |
) |
|
|
— |
|
|
|
(2,444 |
) |
|
|
(2,056 |
) |
|
|
(4,500 |
) |
Other operating income |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,224 |
) |
|
|
— |
|
|
|
(1,224 |
) |
Operating (loss) income |
$ |
(11,403 |
) |
|
$ |
109,011 |
|
|
$ |
97,608 |
|
|
$ |
55,241 |
|
|
$ |
19,720 |
|
|
$ |
74,961 |
|
(1) |
Operating results for the sale of Amneal products by AvKARE were included in our Generics segment. |
|
(2) |
Adjustments for the three months ended March 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense ( |
|
(3) |
Adjustments for the three months ended March 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense ( |
|
(4) |
Adjustments for the three months ended March 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense. |
|
(5) |
Adjustments for the three months ended March 31, 2024 were associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by states, counties, municipalities, and Native American Tribal Nations across the United States. Adjustments for the three months ended March 31, 2023 were comprised of charges for legal proceedings. |
Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)
|
Three Months Ended March 31, 2024 |
|
Three Months Ended March 31, 2023 |
||||||||||||||||||||
|
As Reported |
|
Adjustments |
|
Non-GAAP |
|
As Reported |
|
Adjustments |
|
Non-GAAP |
||||||||||||
Net revenue |
$ |
105,234 |
|
|
$ |
— |
|
|
$ |
105,234 |
|
|
$ |
91,678 |
|
|
$ |
— |
|
|
$ |
91,678 |
|
Cost of goods sold (1) |
|
44,800 |
|
|
|
(25,978 |
) |
|
|
18,822 |
|
|
|
43,191 |
|
|
|
(26,183 |
) |
|
|
17,008 |
|
Gross profit |
|
60,434 |
|
|
|
25,978 |
|
|
|
86,412 |
|
|
|
48,487 |
|
|
|
26,183 |
|
|
|
74,670 |
|
Gross margin % |
|
57.4 |
% |
|
|
|
|
82.1 |
% |
|
|
52.9 |
% |
|
|
|
|
81.4 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Selling, general and administrative (2) |
|
25,196 |
|
|
|
(271 |
) |
|
|
24,925 |
|
|
|
22,379 |
|
|
|
(186 |
) |
|
|
22,193 |
|
Research and development (2) |
|
4,927 |
|
|
|
(284 |
) |
|
|
4,643 |
|
|
|
6,331 |
|
|
|
(389 |
) |
|
|
5,942 |
|
Intellectual property legal development expenses |
|
24 |
|
|
|
— |
|
|
|
24 |
|
|
|
20 |
|
|
|
— |
|
|
|
20 |
|
Restructuring and other charges |
|
946 |
|
|
|
(946 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Change in fair value of contingent consideration (3) |
|
100 |
|
|
|
(100 |
) |
|
|
— |
|
|
|
2,457 |
|
|
|
(2,457 |
) |
|
|
— |
|
Operating income |
$ |
29,241 |
|
|
$ |
27,579 |
|
|
$ |
56,820 |
|
|
$ |
17,300 |
|
|
$ |
29,215 |
|
|
$ |
46,515 |
|
(1) |
Adjustments for the three months ended March 31, 2024 and 2023 were comprised of amortization expense. |
|
(2) |
Adjustments for the three months ended March 31, 2024 and 2023 were comprised of stock-based compensation expense. |
|
(3) |
Contingent consideration was recorded in connection with the acquisitions of (i) the baclofen franchise from certain entities affiliated with Saol International Limited and (ii) Kashiv Specialty Pharmaceuticals, LLC. |
Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(unaudited; $ in thousands)
|
Three Months Ended March 31, 2024 |
|
Three Months Ended March 31, 2023 |
||||||||||||||||||||
|
As Reported |
|
Adjustments |
|
Non-GAAP |
|
As Reported |
|
Adjustments |
|
Non-GAAP |
||||||||||||
Net revenue |
$ |
162,663 |
|
|
$ |
— |
|
|
$ |
162,663 |
|
|
$ |
122,056 |
|
|
$ |
— |
|
|
$ |
122,056 |
|
Cost of goods sold |
|
136,409 |
|
|
|
— |
|
|
|
136,409 |
|
|
|
105,612 |
|
|
|
— |
|
|
|
105,612 |
|
Gross profit |
|
26,254 |
|
|
|
— |
|
|
|
26,254 |
|
|
|
16,444 |
|
|
|
— |
|
|
|
16,444 |
|
Gross margin % |
|
16.1 |
% |
|
|
|
|
16.1 |
% |
|
|
13.5 |
% |
|
|
|
|
13.5 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Selling, general and administrative (2) |
|
14,907 |
|
|
|
(3,545 |
) |
|
|
11,362 |
|
|
|
12,940 |
|
|
|
(3,764 |
) |
|
|
9,176 |
|
Operating income |
$ |
11,347 |
|
|
$ |
3,545 |
|
|
$ |
14,892 |
|
|
$ |
3,504 |
|
|
$ |
3,764 |
|
|
$ |
7,268 |
|
(1) |
Operating results for the sale of Amneal products by AvKARE were included in our Generics segment. |
|
(2) |
Adjustments for the three months ended March 31, 2024 and 2023, respectively, were comprised of amortization expense ( |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503325618/en/
Anthony DiMeo
VP, Investor Relations & Media
anthony.dimeo@amneal.com
Source: Amneal Pharmaceuticals, Inc.
FAQ
What was Amneal Pharmaceuticals Q1 2024 net revenue?
What was the GAAP net loss in Q1 2024 for Amneal Pharmaceuticals?
What is the stock symbol for Amneal Pharmaceuticals?
What is the settlement in principle on a nationwide opioids settlement?
What is Amneal Pharmaceuticals 2024 full-year guidance for net revenue?
